Goodbye to hypos? 9 December 2014 Could hypoglycaemia soon be a thing of the past? A young scientist in the US has developed a non-insulin drug for people with type two diabetes that could help eliminate the risk of low-blood glucose hypos. Some people with type two diabetes use insulin to keep their blood glucose levels in check. If blood-glucose levels become too low, hypoglycaemia can occur and this can be life-threatening. To combat this, Arnab De, a scientist with a PhD in microbiology and immunology at Columbia University, developed a non-insulin drug in collaboration with fellow scientist Richard DiMarchi of Indiana University. “We find that there is a peptide hormone in the gut called GLP1 that increases the secretion of insulin only when the blood glucose is high,” Dr De said. “This effectively eliminates the risk of hypoglycemic shock. Another advantage is that GLP1 administration has been found to stimulate weight-loss. “The hormone offers the promise of revolutionising the treatment of type two diabetes and reduce obesity.” Read the article online at: http://www.diabetesqld.org.au/
Media releases 24 February 2026 Diabetes sector stands together in call for affordable access to technology The diabetes sector across Australia has come together to call for better access to life-changing diabetes technologies. Ahead of the... Continue Reading
News 23 February 2026 Diabetes Australia data secure Diabetes Australia has been contacted regarding a data breach at a diabetes organisation located in Victoria. The breach did not involve Diabetes Australia and we have been advised by... Continue Reading
Media releases 20 February 2026 Diabetes Australia appoints first Chief Health Officer Diabetes Australia has appointed Brett Fenton as its first Chief Health Officer marking a major step in strengthening clinical leadership and improving outcomes for people living with diabetes. Continue Reading